Navigation Links
Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
Date:4/30/2010

WALTHAM, Mass., April 30 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder.  The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.  Repligen is currently enrolling patients in a Phase 2b clinical trial of RG2417, an oral formulation of uridine, to assess its impact on the symptoms of acute depression.  This study is designed to confirm and extend the results of a Phase 2a study in which 6 weeks of treatment with RG2417 improved the symptoms of bipolar depression when compared to placebo as measured by the Montgomery-Asberg Depression Rating Scale.  Repligen has exclusively licensed this patent from McLean Hospital, the largest psychiatric facility of Harvard Medical School.

"We are very pleased with this action by the United States Patent Office covering the use of a potentially important new treatment for bipolar disorder," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "This patent will provide commercial exclusivity for RG2417 in the United States through at least 2025."

This patent may qualify for up to 5 years of patent term extension under the provisions of the Hatch-Waxman Act, subject to certain limitations.  Foreign eq
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
2. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
3. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
6. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
7. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
8. Capstone Reports Additional High Grade Copper-Gold Results From Minto East
9. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
10. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
11. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender ... (NASDAQ: VPHM).   As a result of the ... and Shire expects to complete the tender offer on January ... the satisfaction of all of the remaining conditions to the ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors ... be able to protect their most important ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... Medical Device Industry, it steadfastly remains one ... cases involving IP infringement. This litigious nature ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ... less than 10 bps, yet are surprisingly capable in ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Nasdaq: NVGN ), announced today that following ... held on 7 May, 2012, its Board of Directors ... Marshall Edwards, Inc. ("MEI") under the MEI rights offering ... rights that have not been otherwise exercised by MEI ...
... 2012  Marshall Edwards, Inc. (Nasdaq: MSHL ), ... novel therapeutics targeting cancer metabolism, announced that its majority ... million of Units, subject to availability, in Marshall Edwards, ... Novogen stockholders in Sydney on Monday. Pursuant ...
Cached Medicine Technology:Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering 2Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering 2Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... 30 (HealthDay News) -- Parents who smoke are more likely to ... but their chances of success aren,t any better than normal, a ... an important role in helping these parents quit smoking, said the ... included 1,112 children who lived with at least one person who ...
... health problems have higher mortality rates than patients without ... 30 in the Journal of the National Cancer ... heart attack and other heart-related problems, chronic obstructive pulmonary ... that comorbidities as a group are associated with poorer ...
... consider the impact of gender on patient outcomes in major ... found that women are more likely to survive after the ... comparing women before menopause with men of the same age. ... Surgical Research in a paper titled "The Battle of ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, June ... it is to remember things that never happened, especially if ... British and Israeli researchers used a novel false-memory test and ... About 70 percent of those who took part in the ...
... Johns Hopkins have provided more clues to one of the ... of cellular DNA, called telomeres, lengthen instead of shorten. ... Express, the Johns Hopkins researchers say they have identified ... Telomeres contain repeated sequences of DNA that, in normal ...
... new study published in the American Journal of Transplantation ... skin cancers, including cutaneous squamous cell carcinoma and melanoma, ... they need immune medications to keep their body from ... they experience as a result of the medications can ...
Cached Medicine News:Health News:A Child's Surgery May Prompt Parents to Try to Quit Smoking 2Health News:Worse outcomes for older breast cancer patients with other health problems 2Health News:Women win out in gastrointestinal surgery 2Health News:Group-Think Can Influence Your Memory, Research Shows 2Health News:Telomeres: 2 genes linked to why they stretch in cancer cells 2Health News:Telomeres: 2 genes linked to why they stretch in cancer cells 3
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: